← Leaderboards

Erkki I Ruoslahti

Burnham Institute For Medical Research

Google Scholar ↗PubMed ↗ORCID ↗

$16,537,432

Attributed

$19,020,759

Total exposure

20

Grants

12

Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $1.9M · FY2005–19

$2M$1.5M$1M$500K$0

'05

'06

'07

'08

'09

'10

'11

'12

'13

'14

'15

'16

'17

'18

'19

Funding mix

By agency

NIH$34,195,905 · 22

By mechanism

P01$12,725,582 · 4

R01$12,006,649 · 9

P30$5,893,331 · 2

R44$1,709,711 · 1

R21$1,072,500 · 2

R41$392,094 · 2

Top collaborators

Most similar at Burnham Institute For Medical Research

Same institution · by research overlap

Dorit Hanein$21,041,488
Hudson H Freeze$21,287,214
Jeffrey W Smith$49,666,414

Others in their field

Top investigators on “Peptides”

David M Nathan · Massachusetts Institute Of Technology$118,672,444
John M Lachin · George Washington University$118,672,444
David Heimbrook · Leidos Biomedical Research, Inc.$91,429,616
Michael W Weiner · Northern California Institute Res &Educ$78,425,041
Paul S. Aisen · Cognition Therapeutics, Inc.$69,846,203
Rolf Apweiler · European Molecular Biology Laboratory$56,677,991

Research focus

PeptidesReceptorHomingNeoplasm /Cancer Blood SupplyLaboratory MouseCellsTissuesTumorAngiogenesisPharmaceutical PreparationsBaseAngiogenesis InhibitorsBiomarkerSynthetic PeptideNanoparticleBlood VesselsTumor TissueBacteriophagesPeptide LibraryCancer TherapyDesignMalignant - DescriptorResearch StudyIntegrins

Grant awards (74)

Infection-homing nanosystems as antibacterial therapeutics-delivery platforms$800,521

R01 · FY2019 · AI

Phage Display Detection of Alzheimer's Disease Markers$243,750

R21 · FY2019 · AG · contact PI

Infection-homing nanosystems as antibacterial therapeutics-delivery platforms$805,479

R01 · FY2018 · AI

A nanosystem for tumor treatment and imaging$404,625

R01 · FY2018 · CA · contact PI

Phage Display Detection of Alzheimer's Disease Markers$292,500

R21 · FY2018 · AG · contact PI

New Molecular Signatures in Alzheimer's Disease$243,750

R21 · FY2018 · NS · contact PI

Infection-homing nanosystems as antibacterial therapeutics-delivery platforms$836,708

R01 · FY2017 · AI

A nanosystem for tumor treatment and imaging$404,625

R01 · FY2017 · CA · contact PI

Nanoparticle Transport Through Tissues$300,000

R56 · FY2017 · CA · contact PI

New Molecular Signatures in Alzheimer's Disease$292,500

R21 · FY2017 · NS · contact PI

A NOVEL TARGETED DELIVERY SYSTEM FOR CANCER TREATMENT AND DIAGNOSIS$435,490

R44 · FY2016 · CA

A nanosystem for tumor treatment and imaging$404,625

R01 · FY2016 · CA · contact PI

A NOVEL TARGETED DELIVERY SYSTEM FOR CANCER TREATMENT AND DIAGNOSIS$1,051,862

R44 · FY2015 · CA

A nanosystem for tumor treatment and imaging$404,625

R01 · FY2015 · CA · contact PI

Tumor Penetrating Peptides for Cancer Targeting$404,625

R01 · FY2015 · CA · contact PI

A nanosystem for tumor treatment and imaging$404,625

R01 · FY2014 · CA · contact PI

Tumor Penetrating Peptides for Cancer Targeting$392,486

R01 · FY2014 · CA · contact PI

A NOVEL TARGETED DELIVERY SYSTEM FOR CANCER TREATMENT AND DIAGNOSIS$222,359

R44 · FY2014 · CA

Tumor Penetrating Peptides for Cancer Targeting$380,348

R01 · FY2013 · CA · contact PI

High-throughput screen to identify modulators of CendR-mediated cellular uptake$47,288

R03 · FY2013 · DA · contact PI

Tumor Penetrating Peptides for Cancer Targeting$396,325

R01 · FY2012 · CA · contact PI

High-throughput screen to identify modulators of CendR-mediated cellular uptake$48,750

R03 · FY2012 · DA · contact PI

Tumor Penetrating Peptides for Cancer Targeting$396,325

R01 · FY2011 · CA · contact PI

Injury-targeted decorin for systemic anti-fibrotic treatment$220,390

R41 · FY2011 · GM · contact PI

HOMING PEPTIDES FOR THE VASCULATURE IN PROSTATE$473,208

P01 · FY2009 · CA · contact PI

HOMING PEPTIDES FOR THE VASCULATURE IN PROSTATE$462,715

P01 · FY2008 · CA · contact PI

Regulation of Apoptosis by Integrin$422,336

P01 · FY2008 · CA · contact PI

Molecular Specialization of Tumor Lymphatics$171,323

R01 · FY2008 · CA · contact PI

HOMING PEPTIDES FOR THE VASCULATURE IN PROSTATE$458,895

P01 · FY2007 · CA · contact PI

Regulation of Apoptosis by Integrin$418,278

P01 · FY2007 · CA · contact PI

Regulation of Apoptosis by Integrins$271,654

R01 · FY2007 · CA · contact PI

Molecular Specialization of Tumor Lymphatics$171,323

R01 · FY2007 · CA · contact PI

ANGIOGENESIS INHIBITORS: A MECHANISM OF ACTION$375,444

R01 · FY2006 · CA · contact PI

HOMING PEPTIDES FOR THE VASCULATURE IN PROSTATE$291,349

P01 · FY2006 · CA · contact PI

Regulation of Apoptosis by Integrins$279,767

R01 · FY2006 · CA · contact PI

Regulation of Apoptosis by Integrin$217,484

P01 · FY2006 · CA · contact PI

Molecular Specialization of Tumor Lymphatics$176,440

R01 · FY2006 · CA · contact PI

ANGIOGENESIS INHIBITORS: A MECHANISM OF ACTION$384,480

R01 · FY2005 · CA

Regulation of Apoptosis by Integrins$286,500

R01 · FY2005 · CA

HOMING PEPTIDES FOR THE VASCULATURE IN PROSTATE$283,354

P01 · FY2005 · CA

Regulation of Apoptosis by Integrin$211,149

P01 · FY2005 · CA

Molecular Specialization of Tumor Lymphatics$180,686

R01 · FY2005 · CA

TARGETING OF TUMOR VASCULATURE$1,982,836

P01 · FY2004 · CA

Regulation of Apoptosis by Integrins$391,550

R01 · FY2004 · CA

ANGIOGENESIS INHIBITORS: A MECHANISM OF ACTION$384,480

R01 · FY2004 · CA

Regulation of Apoptosis by Integrin$204,999

P01 · FY2004 · CA

TARGETING OF TUMOR VASCULATURE$2,084,506

P01 · FY2003 · CA

ANGIOGENESIS INHIBITORS: A MECHANISM OF ACTION$384,480

R01 · FY2003 · CA

TARGETING OF TUMOR VASCULATURE$122,309

P01 · FY2003 · CA

TARGETING OF TUMOR VASCULATURE$1,950,442

P01 · FY2002 · CA

INTEGRIN REGULATION BY R-RAS$280,642

R01 · FY2002 · CA

TARGETING OF TUMOR VASCULATURE$277,416

P01 · FY2002 · CA

TARGETING OF TUMOR VASCULATURE$119,323

P01 · FY2002 · CA

PHAGE PROFILING ANGIOGENICS STAGES IN TUMORIGENESIS$76,163

P01 · FY2002 · CA

VASCULAR TARGETING WITH PHAGE LIBRARIES$0

P01 · FY2002 · CA

CORE--DEVELOPMENTAL FUNDS$0

P30 · FY2002 · CA

VASCULAR TARGETING WITH PHAGE LIBRARIES$0

P01 · FY2002 · CA

VASCULAR TARGETING WITH PHAGE LIBRARIES$0

P01 · FY2002 · CA

VASCULAR TARGETING WITH PHAGE LIBRARIES$0

P01 · FY2002 · CA

CANCER CENTER SUPPORT GRANT$2,885,314

P30 · FY2001 · CA

TARGETING OF TUMOR VASCULATURE$1,355,391

P01 · FY2001 · CA

TUMOR CELLS IN CIRCULATION$365,333

R01 · FY2001 · CA

TISSUE TARGETING WITH PHAGE LIBRARIES$289,723

R01 · FY2001 · CA

INTEGRIN REGULATION BY R-RAS$273,254

R01 · FY2001 · CA

New Anti-Metastatic and Anti-Angiogenic Compounds$171,704

R41 · FY2001 · CA

CORE--DEVELOPMENTAL FUNDS$0

P30 · FY2001 · CA

VASCULAR TARGETING WITH PHAGE LIBRARIES$0

P01 · FY2001 · CA

CANCER CENTER SUPPORT GRANT$3,008,017

P30 · FY2000 · CA

TARGETING OF TUMOR VASCULATURE$1,313,429

P01 · FY2000 · CA

TUMOR CELLS IN CIRCULATION$355,442

R01 · FY2000 · CA

TISSUE TARGETING WITH PHAGE LIBRARIES$282,108

R01 · FY2000 · CA

INTEGRIN REGULATION BY R-RAS$266,078

R01 · FY2000 · CA

CORE--DEVELOPMENTAL FUNDS$0

P30 · FY2000 · CA

VASCULAR TARGETING WITH PHAGE LIBRARIES$0

P01 · FY2000 · CA